Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypereosinophilic syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Hypereosinophilic syndrome. Displaying page 1 of 1.
    EudraCT Number: 2004-000929-30 Sponsor Protocol Number: MHE100185 Start Date*: 2004-07-08
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase III Study to Evaluate Corticosteroid-reduction and -sparing Effects of Mepolizumab 750 mg Intravenous in Subjects w...
    Medical condition: HES
    Disease: Version SOC Term Classification Code Term Level
    6.1 10048643 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000930-35 Sponsor Protocol Number: MHE100901 Start Date*: 2005-05-26
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: An open-label extension study to study 100185, to evaluate long-term safety, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome.
    Medical condition: HES
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005692-39 Sponsor Protocol Number: 217013 Start Date*: 2022-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES)
    Medical condition: Hypereosinophilic Syndrome (HES)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000184-32 Sponsor Protocol Number: 205203 Start Date*: 2017-09-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622
    Medical condition: Hypereosinophilic syndrome (HES)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) PL (Completed) Outside EU/EEA IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000933-15 Sponsor Protocol Number: 215360 Start Date*: 2022-01-31
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.
    Medical condition: Hypereosinophilic syndrome (HES)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000838-39 Sponsor Protocol Number: MHE104317 Start Date*: 2007-10-11
    Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd
    Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome
    Medical condition: Hypereosinophilic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002039-27 Sponsor Protocol Number: D3254C00001 Start Date*: 2020-01-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients wi...
    Medical condition: Hypereosinophilic Syndrome (HES)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001232-11 Sponsor Protocol Number: 200622 Start Date*: 2016-11-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophi...
    Medical condition: severe hypereosinophilic syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001483-51 Sponsor Protocol Number: CAMN107A2101 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated ph...
    Medical condition: CML in chronic phase, accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002280-24 Sponsor Protocol Number: NILG-HES 1-03 Start Date*: 2004-07-26
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A ST...
    Medical condition: HYPEREOSINOPHILIC SYNDROME (HES, CEL, CIH)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024324 HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001768-95 Sponsor Protocol Number: 0420-20 Start Date*: 2021-03-31
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWOSEQUENCE, SINGLE ORAL DOSE, CROSSOVER, COMPARATIVE BIOAVAILABILITY STUDY OF IMATINIB ORAL SOLUTION 800 MG/10 ML (AT A DOSE OF 05 M...
    Medical condition: Healthy volunteers (Chronic Myeloid Leukaemia, Acute Lymphoblastic Leukaemia, Myelodysplastic/myeloproliferative diseases, advanced hypereosinophilic syndrome and/or chronic eosinophilic leukaemia)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 08:42:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA